TY - JOUR AU - Gozzetti, Alessandro AU - Bacchiarri, Francesca AU - Sammartano, Vincenzo AU - Defina, Marzia AU - Sicuranza, Anna AU - Mecacci, Bianca AU - Zappone, Elisabetta AU - Cencini, Emanuele AU - Fabbri, Alberto AU - Raspadori, Donatella AU - Bocchia, Monica PY - 2020 M3 - Brief Research Report TI - Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients JO - Frontiers in Oncology UR - https://www.frontiersin.org/articles/10.3389/fonc.2020.570187 VL - 10 SN - 2234-943X N2 - Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients. ER -